Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vietnam To Review Approval Process For Merck and GSK Cancer Vaccines After Reports Of Unethical Lobbying, Efficacy Concerns

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - Vietnam's Ministry of Health has decided to review the approval process of two cervical cancer vaccines -Gardasil of Merck Sharp & Dohme and GlaxoSmithKline's Cervarix, the ministry announced Dec. 17

You may also be interested in...



Japan's MHLW Says HPV DNA Testing “Unnecessary” In Cervical Cancer Screening Guidelines

Japan's Ministry of Health, Labor and Welfare's research team Dec. 8 issued a finding on the use of human papillomavirus DNA testing for cervical cancer screening. According to the report, the team concluded that it was insufficient to prove that HPV testing lowered cervical cancer death rates, and the team recommended that testing not be included in the regular medical checklist

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel